Vistagen reports fiscal year 2025 second quarter financial results and corporate update

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended september 30, 2024, and provided a corporate update. “we initiated our palisade-4 phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol u.s. registration-directed phase 3 program for the acute t.
VTGN Ratings Summary
VTGN Quant Ranking